Evidence map›Paper›PMID 40153062›Full record

ReviewSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2025

Preventing chemotherapy-induced ovarian damage through PI3K/AKT and Hippo pathway regulation.

Negin Zatalian, Azam Dalman, Hamid Gourabi

Abstract readReview
PubMed Publisher
In one paragraph

Review in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Negin ZatalianDepartment of Molecular Cell Biology-Genetics, Faculty of Basic Sciences and Advanced Technologies in Biology, University of Science and Culture, Tehran, Iran.
Azam DalmanDepartment of Embryology, Reproductive Biomedicine Research Center, Royan Institute for Reproductive Biomedicine, ACECR, Tehran, Iran. a.dalman@royan-rc.ac.ir.
Hamid GourabiDepartment of Genetics, Reproductive Biomedicine Research Center, Royan Institute for Reproductive Biomedicine, ACECR, Tehran, Iran. gourabi@royaninstitute.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Advances in cancer treatment have increased survival rates; however, chemotherapy drugs can impair ovarian reserve via pathways such as PI3K/AKT and Hippo, leading to infertility. Conventional fertility preservation options have limitations. Therefore, agents that prevent or reduce the ovarian side effects of chemotherapy should be investigated. This review explored treatments for preserving ovarian reserve by regulating the PI3K/AKT and Hippo pathways during chemotherapy. When treated with cyclophosphamide and cisplatin, 33 agents in the articles were implicated in the PI3K/AKT and/or Hippo pathways, most of which target the PI3K/AKT pathway. It can be concluded that controlling both the PI3K/AKT and Hippo pathways, but specifically the PI3K/AKT pathway, can help maintain ovarian reserve against these two chemotherapy drugs and provide hope for increased fertility in patients receiving chemotherapy.

Indexed as

Antineoplastic AgentsCisplatinCyclophosphamideFemaleFertility PreservationHippo Signaling PathwayHumansNeoplasmsOvarian ReserveOvaryPhosphatidylinositol 3-KinasesProtein Serine-Threonine KinasesProto-Oncogene Proteins c-aktSignal TransductionAntineoplastic AgentsCisplatinCyclophosphamidePhosphatidylinositol 3-KinasesProtein Serine-Threonine KinasesProto-Oncogene Proteins c-aktCisplatinCyclophosphamideHippo pathwayOvarian reservePI3K/AKT pathway

Identifiers

PMID40153062

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.